Search hospitals > Louisiana > New Orleans
Louisiana State University Health Science Center
Claim this profileNew Orleans, Louisiana 70112
Global Leader in Cancer
Global Leader in Breast Cancer
Conducts research for Lung Cancer
Conducts research for Non-Small Cell Lung Cancer
Conducts research for High Blood Pressure
254 reported clinical trials
21 medical researchers
Summary
Louisiana State University Health Science Center is a medical facility located in New Orleans, Louisiana. This center is recognized for care of Cancer, Breast Cancer, Lung Cancer, Non-Small Cell Lung Cancer, High Blood Pressure and other specialties. Louisiana State University Health Science Center is involved with conducting 254 clinical trials across 491 conditions. There are 21 research doctors associated with this hospital, such as Scott E. Delacroix, Brian C. Boulmay, Augusto C. Ochoa, and Agustin Garcia, M.D..Area of expertise
1Cancer
Global LeaderStage IV
Stage III
Stage II
2Breast Cancer
Global LeaderER positive
HER2 positive
Stage IV
Top PIs
Scott E. DelacroixLSU Healthcare Network / Metairie Multi-Specialty Clinic2 years of reported clinical research
Expert in Prostate Cancer
Expert in Cancer
26 reported clinical trials
61 drugs studied
Brian C. BoulmayUniversity Medical Center New Orleans4 years of reported clinical research
Studies Cancer
Studies Lung Cancer
17 reported clinical trials
27 drugs studied
Augusto C. OchoaGulfport Memorial Hospital7 years of reported clinical research
Studies Breast Cancer
Studies Cancer
15 reported clinical trials
69 drugs studied
Agustin Garcia, M.D.University Medical Center New Orleans8 years of reported clinical research
Studies Breast Cancer
Studies Tumors
9 reported clinical trials
18 drugs studied
Clinical Trials running at Louisiana State University Health Science Center
Breast Cancer
Bladder Cancer
Cancer
Non-Small Cell Lung Cancer
Renal Cell Carcinoma
Bladder Carcinoma
Lung Cancer
Squamous Cell Carcinoma
Ovarian Cancer
Cervical Cancer
Shorter Chemo-Immunotherapy Without Anthracyclines
for Breast Cancer
This phase III trial compares the effects of shorter chemotherapy (chemo)-immunotherapy without anthracyclines to usual chemo-immunotherapy for the treatment of early-stage triple negative breast cancer. Paclitaxel is in a class of medications called anti-microtubule agents. It stops cancer cells from growing and dividing and may kill them. Carboplatin is in a class of medications known as platinum-containing compounds. It works in a way similar to the anticancer drug cisplatin, but may be better tolerated than cisplatin. Carboplatin works by killing, stopping or slowing the growth of cancer cells. Cyclophosphamide is in a class of medications called alkylating agents. It works by damaging the cell's deoxyribonucleic acid (DNA) and may kill cancer cells. It may also lower the body's immune response. Docetaxel is in a class of medications called taxanes. It stops cancer cells from growing and dividing and may kill them. Doxorubicin is an anthracycline chemotherapy drug that damages DNA and may kill cancer cells. Pembrolizumab may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Shorter treatment without anthracycline chemotherapy may work the same as the usual anthracycline chemotherapy treatment for early-stage triple negative breast cancer.
Recruiting2 awards Phase 347 criteria
Chemotherapy + Hormone Therapy
for Breast Cancer
This trial is testing if adding additional cancer-fighting drugs to treatments that stop certain body functions is better than just using the treatments that stop those functions alone. It targets younger women with early-stage breast cancer who have a higher risk of dying from the disease. The treatment works by stopping certain body functions and using drugs to kill cancer cells.
Recruiting2 awards Phase 319 criteria
Alpelisib + Tucatinib
for Breast Cancer
This trial tests a combination of two drugs, tucatinib and alpelisib, in patients with a specific type of advanced breast cancer. These patients have a genetic mutation and a type of cancer that may not respond well to standard treatments. The drugs work by blocking signals that help cancer cells grow. Alpelisib is approved for treating certain types of advanced breast cancer.
Recruiting1 award Phase 1 & 211 criteria
Similar Hospitals nearby
Frequently asked questions
What kind of research happens at Louisiana State University Health Science Center?
Louisiana State University Health Science Center is a medical facility located in New Orleans, Louisiana. This center is recognized for care of Cancer, Breast Cancer, Lung Cancer, Non-Small Cell Lung Cancer, High Blood Pressure and other specialties. Louisiana State University Health Science Center is involved with conducting 254 clinical trials across 491 conditions. There are 21 research doctors associated with this hospital, such as Scott E. Delacroix, Brian C. Boulmay, Augusto C. Ochoa, and Agustin Garcia, M.D..